Pfizer, Roche join $42.6M round to fund microbiome player Second Genome
Second Genome uses genomics, computational biology and phenotypic screening to identify the molecular mechanisms of the microbiome that cause disease.
Nestlé Health Science expanding biotech investment
Nestlé is expanding its tentacles from chocolatier into drug development – investing in companies focused on microbiota, muscle loss and Alzheimer’s disease. STAT talked with Greg Behar, CEO of the new Nestlé Health Science subsidiary of the company, on the company’s foray into the life sciences. The company’s health science subsidiary was launched five years ago, and employs […]
A Deep-dive Into Specialty Pharma
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Seres Health adds Mayo Clinic in $10M series B to advance microbiome therapeutics
Seres Health has raised $10 million to advance its C.difficile therapeutic to treat strains resistant to the antibiotic vancomycin, according to a company statement. It wants to combat the increasing threat hospital acquired infections pose to patients. But this innovative approach to medicine also faces some regulatory challenges. The Mayo Clinic was among the new […]